Chardan Capital Reaffirms Their Buy Rating on Dicerna Pharma (DRNA)

By Ryan Adsit

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Dicerna Pharma (DRNAResearch Report), with a price target of $25.00. The company’s shares closed last Thursday at $22.85.

According to, Nakae is a 4-star analyst with an average return of 6.1% and a 46.5% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Arcturus Therapeutics, and NeuBase Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dicerna Pharma with a $34.14 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $27.69 and a one-year low of $10.70. Currently, Dicerna Pharma has an average volume of 658.7K.

Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DRNA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.